Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Studiendesign einer offenen, prüferverblindeten Phase-3-Studie (START UP) zum Vergleich von Sicherheit und Wirksamkeit von Upadacitinib mit Dupilumab bei Kindern von 2 bis unter 12 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s859
DOI: 10.25251/esydg329 ↗Auf einen Blick
START UP ist eine laufende Phase-3-Studie bei Kindern von 2 bis unter 12 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis. Untersucht werden Wirksamkeit, Sicherheit und Dosierung von Upadacitinib im Vergleich zu Dupilumab.
Fragestellung
Wie schneiden Upadacitinib und Dupilumab bei Kindern von 2 bis unter 12 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis bezüglich Wirksamkeit und Sicherheit ab?
Methode
Offene, prüferverblindete Phase-3-Studie (START UP, NCT06461897) mit Screening über 35 Tage, Behandlungsphase bis Woche 160 und Nachbeobachtung. Vergleich von Upadacitinib mit Dupilumab; Sicherheitsbewertung über die gesamte Studie.
Ergebnisse
Die Rekrutierung und Nachbeobachtung laufen noch. Primäre Wirksamkeitsziele sind EASI-75 in Ländern außerhalb der USA sowie vIGA-AD 0/1 mit ≥ 2-Punkte-Verbesserung in den USA und China in Woche 16.
Schlussfolgerung der Autor:innen
Die laufende START UP-Studie wird die Wirksamkeit und Sicherheit von Upadacitinib im Vergleich zu Dupilumab bei Kindern von 2 bis unter 12 Jahren prüfen und die Dosisoptimierung untersuchen.
Kernaussagen
- Laufende Phase-3-Studie bei Kindern von 2 bis unter 12 Jahren
- Vergleich von Upadacitinib mit Dupilumab
- Primäre Endpunkte in Woche 16; Sicherheitsbewertung über die gesamte Studie
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Amy Paller und 10 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction & Objectives While phase 3 studies established the safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, for treatment of atopic dermatitis (AD) in adults and adolescents,1-3 it is important to evaluate its safety, efficacy, and optimal dosing in the younger pediatric population. START UP is an ongoing open-label, efficacy-assessor-blinded, phase 3 study comparing UPA to dupilumab in children from 2 to < 12 years of age for the treatment of moderate to severe AD. Materials & Methods START UP (NCT06461897) is comprised of a 35-day screening period, an open-label treatment period (week 0 to 160; assessor-blinded up to week 16) and a follow-up period. Eligible patients are 2 to < 12 years of age with moderate to severe AD. In one cohort, patients with inadequate response (IR) to systemic therapy or intolerance of topical corticosteroids and/or topical calcineurin inhibitors or dupilumab-exposed patients without IR will be randomized 3:1:1 to receive an adult equivalent weight-based dose of UPA 15mg, an adult equivalent weight-based dose of UPA 7.5mg, or a label-indicated dose of dupilumab. In the second cohort, patients with IR or intolerance of dupilumab (dupilumab-IR) or for whom dupilumab is medically inadvisable will be treated with an adult equivalent weight-based dose of UPA 15mg. UPA will be administered as an oral solution twice a day (BID) or, for patients ≥ 30kg, as an oral tablet once daily (QD). Patients will be followed for 30 days after the last dose of UPA and for 12 weeks after the last dose of dupilumab. In countries other than the USA, the primary efficacy objective is to assess the proportion of patients achieving ≥75% improvement in Eczema Area and Severity Index (EASI-75) at week 16 in patients treated with UPA 15mg compared with those treated with dupilumab. In the USA and China, the primary, descriptive efficacy objective is to assess the proportion of patients achieving validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) 0 or 1 with a reduction from baseline of ≥ 2 points at week 16 in each treatment group, with dupilumab as the reference arm for UPA 15mg. From Week 20 to Week 40, patients not achieving EASI-75 will be eligible for dose escalation: those on UPA 7.5 mg may increase to UPA 15 mg, with further escalation to UPA 30 mg if EASI-75 is still not achieved; patients on UPA 15 mg may escalate directly to UPA 30 mg. At week 52, a dose reduction will be mandatory for patients who achieve EASI-90 with UPA 15mg or UPA 30mg. No dose changes will be permitted with dupilumab. Safety will be assessed throughout the study.
Results
Recruitment and follow-up for the START-UP study are ongoing.
Conclusion
The ongoing START UP study will compare the efficacy and safety of UPA to dupilumab in children aged 2 to < 12 years with moderate to severe AD, evaluate UPA in dupilumab-IR or dupilumab medically inadvisable patients, and assess dose optimization.
Zitieren
APA
Paller, A., Prajapati, V., Blume-Peytavi, U., Aoki, V., Ma, L., Lee, L. W., Beckers, V., Levy, G., Goel, S., Teixeira, H., & Irvine, A. (2026). Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 10(6), s859. https://doi.org/10.25251/esydg329
Vancouver
Paller A, Prajapati V, Blume-Peytavi U, Aoki V, Ma L, Lee LW, et al. Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s859. doi:10.25251/esydg329
BibTeX
@article{Paller2026,
author = {Paller, Amy and Prajapati, Vimal and Blume-Peytavi, Ulrike and Aoki, Valeria and Ma, Lin and Lee, Lara Wine and Beckers, Vera and Levy, Gweneth and Goel, Shilpa and Teixeira, Henrique and Irvine, Alan},
title = {Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s859},
doi = {10.25251/esydg329}
}
EUVIMED